Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12207313 | 0.83 | AGXT (0.38) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL27916481 | 0.81 | ACHE (0.37) | HSP90AA1HSP90AB1MAOAALDH1A1 | |
| SCHEMBL27916480 | 0.81 | AGXT (0.41) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL16921630 | 0.79 | AGXT (0.46) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL94923 | 0.77 | AGXT (0.53) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL191370 | 0.76 | ALDH1A1 (0.38) | AGXTHSP90AA1HSP90AB1ALDH1A1KMT2A | |
| SCHEMBL31922 | 0.76 | AGXT (0.49) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL2629579 | 0.76 | AGXT (0.49) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL26281215 | 0.76 | AGXT (0.43) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL29039529 | 0.76 | AGXT (0.52) | AGXTHSP90AA1HSP90AB1TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402349-B1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2810945-A1 | Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative | Daiichi Sankyo Company, Limited (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8846703-B2 | Crystal of a free tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846703-B2 | Crystal of a free tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846703-B2 | Crystal of a free tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8815880-B2 | Crystal of tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8815880-B2 | Crystal of tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2402349-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| WO-2010098344-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | AGXT 3394/4885HSP90AA1 3/4885HSP90AB1 1/4885 |
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | HSP90AB2P, HSP90B1, HSP90AA1 | AGXT 2787/4885HSP90AA1 3/4885HSP90AB1 4/4885 |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | AGXT 3394/4885HSP90AA1 3/4885HSP90AB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.